Rescheduling Raises a Big Question: Is the DEA Poised To Become the Nation’s Biggest Weed Dealer?

The Trump administration’s cannabis rescheduling order arrived this week with a mix of anticipation and confusion. The move marks the most significant federal shift in cannabis policy in decades, but the practical impact will not be clear until the Department of Justice and the Drug Enforcement Administration release the rules governing how rescheduling will work in practice. Until then, operators and attorneys are left reading between the lines while also expecting legal challenges from prohibitionist groups determined to stop the policy before it takes effect.

One provision in particular has sparked early debate: a requirement that the DEA purchase and then resell state‑legal medical cannabis at a nominal price to satisfy the United States’ obligations under the Single Convention on Narcotic Drugs, an international treaty on drug enforcement. Attorney Marc Hauser, who writes the Cannabis Musings Substack and serves as general counsel at Khalifa Kush, as well as chief of staff and director at Las Vegas dispensary Jardín, highlighted the issue in a recent post. 

He summarized the mechanism this way: “I’m not making this up, the DEA will buy and sell cannabis.”

That line raised an obvious question that now sits at the center of the industry’s early reaction: could the agency historically tasked with suppressing cannabis end up functioning as the nation’s biggest weed dealer? 

I spoke with Hauser, who also teaches cannabis law at UNLV, to understand what the rule actually says and what it might mean.

A Treaty Workaround With Limited Clarity

Hauser said the structure appears designed to satisfy the treaty’s requirement that a government agency serve as the exclusive purchaser of cannabis production. He believes the administration intends the process to be largely procedural rather than a new federal bottleneck.

“It seems like the intent is to make it sort of a perfunctory process,” he said in an online interview, noting that the DOJ appears focused on avoiding treaty violations rather than inserting the DEA into the commercial flow of cannabis.

 “They don’t want to make this a barrier to access for medical cannabis,” he said.

Still, the order leaves major implementation questions unanswered. The DEA would have access to facilities until the transaction is complete, and the agency would be responsible for auditing and overseeing registered manufacturers. Whether that oversight ends up being light or heavy is unknown.

“There are definitely ways that DEA could make life a little more difficult,” Hauser said. “But I don’t really see that happening in a way that’s going to bring things to a halt.” 

He described himself as “modestly optimistic,” noting that this is not his usual posture.

A Second Legal Expert Calls the Structure ‘Bizarre’

Irina Dashevsky, co‑chair of the cannabis practice at Greenspoon Marder, agreed that the mechanism is unusual and said the lack of detail makes it difficult to predict how burdensome it will be.

“I do think it’s bizarre,” she said. “I’m not aware of the DEA taking possession of any other Schedule III drug.” 

She expects the purchase‑and‑resale requirement to function more like paperwork than literal federal handling of cannabis, but she emphasized that the order leaves too many blanks to be confident.

Dashevsky said most state‑licensed facilities already operate under strict inspection and security rules, which could make DEA registration manageable if the agency builds on existing systems. But if the DEA requires pharmaceutical‑grade retrofits, the burden could be significant.

“It really depends on the meat that needs to go on the bone,” she said. “This could become a major compliance burden. It really just depends.”

She also raised a question that many operators are now asking: whether DEA‑licensed medical producers and retailers could legally transact across state lines. The order does not answer that, but she sees a plausible reading that suggests interstate commerce could open for entities that obtain the new federal license.

Small Operators See a Different Risk

While attorneys focus on compliance and treaty mechanics, operators are already thinking about who will participate in whatever system emerges. Micah Sherman, founder of Washington craft brand Raven, said the structure could tilt toward large, well‑capitalized companies.

“They’re going to have this DEA monopoly relationship with the purchase of cannabis,” he said. “And I don’t see me, or anybody like me, or that I know, getting to participate in that sort of relationship as we try to sell our small amounts of flowers to the people in our communities.”

Sherman’s concern reflects a broader fear among small and independent operators that the new framework could create a federal gatekeeper that favors multistate companies with compliance teams and capital reserves. Adult‑use businesses like Raven are not included in the order at all, which only deepens the worry that smaller operators will be left out of whatever system emerges, even if the DEA ultimately intends the process to be straightforward.

The Medical‑Only Split Adds More Complexity

Like Sherman, both Hauser and Dashevsky noted that the order reschedules only state‑legal medical cannabis, leaving adult‑use products in Schedule I. Dashevsky called the distinction “nonsensical,” pointing out that the Controlled Substances Act schedules substances, not consumer intent.

“It’s the same plant, it’s the same products,” she said. “The notion that your purpose for consuming it is what drives whether it’s Schedule I or Schedule III is preposterous.”

She expects the split to put pressure on Congress to pass companion legislation, especially in banking and financial services. She has been involved in federal lobbying on that front for years and believes the timing is now favorable for bills like SAFE Banking to advance.

A Historic Shift With a Long Road Ahead

For all the uncertainty, Dashevsky said the order represents the first meaningful federal cannabis reform in roughly half a century. She sees it as the opening move in what could become a broader federal overhaul, assuming Congress and federal agencies follow through with the necessary implementation work.

But that implementation work is the part no one can see yet. The DEA will need to define licensing standards, explain how the purchase‑and‑resale mechanism works in practice, and clarify how the medical‑only split interacts with existing state markets. The DOJ will need to fill in the legal framework. And the courts will almost certainly be asked to weigh in once prohibitionist groups file their expected challenges.

Until then, the industry is left with a provocative possibility: that the DEA could soon become, at least on paper, a central buyer and reseller of medical cannabis. Whether that makes the agency a treaty‑compliance middleman or something closer to a federally sanctioned cannabis distributor is a question that will not be answered until the government releases the rules that give this order its real shape.